Try our beta test site
63 studies found for:    Lymphoma [CONDITION] AND vorinostat [TREATMENT]
Show Display Options
Rank Status Study
1 Terminated
Has Results
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Conditions: Relapsed Lymphomas;   Refractory Lymphomas
Interventions: Drug: Vorinostat;   Drug: Pegylated Liposomal Doxorubicin (PLD), Doxil
2 Completed Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
Condition: Lymphoma
Interventions: Drug: azacytidine;   Drug: vorinostat
3 Terminated Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat
4 Active, not recruiting Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Condition: Cutaneous T-Cell Lymphoma
Interventions: Biological: KW-0761;   Drug: Vorinostat
5 Withdrawn Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Vorinostat in combination with Bortezomib
6 Terminated Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Conditions: Cutaneous Lymphoma;   Cutaneous T-cell Lymphoma
Interventions: Procedure: TSEBT;   Drug: Vorinostat
7 Completed Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
Condition: Lymphoma
Interventions: Drug: Drug: Carfilzomib;   Drug: Vorinostat
8 Completed
Has Results
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Condition: Lymphoma
Intervention: Drug: vorinostat
9 Terminated
Has Results
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Vorinostat;   Drug: Bortezomib
10 Active, not recruiting Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: vorinostat
11 Completed A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)
Condition: Lymphoma
Intervention: Drug: vorinostat
12 Completed An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
Condition: B-cell Lymphoma
Intervention: Drug: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
13 Completed Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
Condition: Lymphoma
Interventions: Drug: Vorinostat;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Infusion;   Drug: Rituximab;   Drug: G-CSF;   Drug: Palifermin;   Drug: Dexamethasone acetate
14 Terminated Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)
Condition: Peripheral T-Cell Non-Hodgkin's Lymphoma
Intervention: Drug: Vorinostat, Lenalidomide
15 No longer available Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)
Condition: Lymphoma, T-Cell, Cutaneous
Intervention: Drug: Comparator: vorinostat
16 Terminated
Has Results
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
Condition: Lymphoma
Interventions: Drug: vorinostat;   Drug: Comparator: bexarotene
17 Active, not recruiting Vorinostat in Children
Condition: Children With Relapsed Solid Tumor, Lymphoma or Leukemia
Intervention: Drug: zolinza/vorinostat
18 Completed
Has Results
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Drug: vorinostat;   Other: Correlative studies
19 Recruiting Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Vorinostat;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Drug: Rituximab;   Drug: Dexamethasone;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine;   Drug: Enoxaparin;   Procedure: Stem Cell Transplant;   Drug: Palifermin
20 Terminated A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Eltrombopag and Vorinostat

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.